Protective efficacy of mutant strains of Borrelia burgdorferi as potential reservoir host-targeted biologics against Lyme disease

This study demonstrates that non-infectious mutant strains of *Borrelia burgdorferi* and their derived lipoproteins can serve as effective biologics to elicit protective immunity in reservoir hosts, thereby blocking the acquisition of the pathogen by ticks and disrupting the enzootic transmission cycle of Lyme disease.

The Gist

The Problem: The Lyme Disease "Burglar"

Imagine Lyme disease as a very persistent burglar named Borrelia burgdorferi (let's call him "Borrelia"). Borrelia doesn't break into houses (humans) directly. Instead, he hires a delivery service: the tick.

Here is how the cycle works:

1. The Reservoir: Borrelia lives in wild animals like mice (the "Reservoir Hosts").
2. The Pickup: A baby tick (larva) bites a mouse to get a meal. If the mouse is infected, the tick picks up Borrelia.
3. The Delivery: The tick grows up, bites a human, and drops Borrelia off, causing Lyme disease.

The problem is that we can't vaccinate every wild mouse in the forest. And there is no vaccine for humans yet. So, scientists are trying to stop the "pickup" at the source. They want to teach the mice to fight back so the ticks leave empty-handed.

The Strategy: The "Fake Burglar" Training Camp

The scientists in this paper came up with a brilliant, slightly counter-intuitive idea: Use a "fake" version of the burglar to train the mice's immune system.

They created three special "mutant" versions of Borrelia. Think of these mutants as clones that are wearing bright neon signs saying "I AM A BURGLAR!" but are too clumsy to actually break into the house.

• Mutant 1 (ΔbadR): This version has its "off switch" broken. It screams "I'm here!" by showing off a massive parade of its weapons (proteins), but it's so loud and chaotic that the mouse's immune system kicks it out immediately.
• Mutant 2 (8S): This version has its "storage manager" broken. It also overloads the mouse with its weapons, making it impossible for the real burglar to hide.
• Mutant 3 (ML23): This one is missing a key tool (a specific plasmid) it needs to survive in a mouse. It's like a burglar who forgot his lock-picking set; he shows up, gets spotted, and is thrown out.

The Experiment:
The scientists injected these "clumsy, neon-sign" mutants into mice.

• The Result: The mice's immune systems went into overdrive. They saw all those flashing neon signs (the mutant proteins) and created a massive army of antibodies (security guards) to hunt them down.
• The Twist: Because the mutants were harmless, the mice didn't get sick. But they were now super-trained.

The Test: The Real Heist

Next, the scientists introduced the real, dangerous Borrelia into these trained mice.

• What happened? The mice's immune systems recognized the real burglar instantly because he looked just like the "neon sign" mutants they had seen before. They swarmed the real burglar and neutralized him before he could hide in the tissues.
• The Tick Test: Then, they let baby ticks feed on these super-protected mice.
  • Untrained mice: The ticks fed, picked up the real burglar, and left with a full load.
  • Trained mice: The ticks tried to feed, but the mouse's immune system killed the burglar in the blood before the tick could grab him. The ticks left empty-handed.

The Verdict: The "neon sign" mutants successfully stopped the ticks from stealing the disease.

The "Cocktail" Approach: Purified Weapons

The scientists also asked: Do we need the whole "clumsy mutant" bacteria, or can we just use their weapons?

They took the "weapons" (lipoproteins) off the mutants, purified them, and made a vaccine cocktail.

• They injected this cocktail into mice.
• Result: It worked just as well as the live mutants! The mice built a strong defense. When challenged with the real burglar and ticks, the ticks were blocked again.

This is huge because it means we don't need to use live bacteria (which can be risky). We can just use the "parts" of the bacteria to make a safe vaccine.

Why This Matters: The "Oral Bait" Dream

The ultimate goal of this research isn't just to vaccinate lab mice in a cage. It's to create an oral bait.

Imagine putting a treat in the forest that contains this "neon sign" vaccine. A wild mouse eats it, gets vaccinated, and becomes immune.

• When a tick bites that mouse, it gets nothing.
• The tick grows up and bites a human, but it has no disease to give.
• The Cycle is Broken.

The Bottom Line

This paper proves that we can stop Lyme disease by tricking the reservoir animals (mice) into building a super-strong immune shield. By using "broken" versions of the bacteria that act like a wanted poster, we can teach the mice to recognize and destroy the real threat before it ever reaches a human.

It's like putting up "Wanted" posters of the burglar all over the neighborhood so that when the real burglar shows up, every dog in the neighborhood barks and chases him away before he can steal anything.

Technical Summary

1. Problem Statement

Lyme disease (LD), caused by Borrelia burgdorferi (Bb), is the most prevalent vector-borne disease in the United States, with an estimated 476,000 cases annually. Current prevention relies on avoiding tick bites, as no human vaccine is currently available. The enzootic transmission cycle involves Ixodes scapularis ticks and vertebrate reservoir hosts (e.g., mice).

• The Gap: There is a critical need for strategies to interrupt the transmission cycle at the reservoir host level.
• The Challenge: Traditional subunit vaccines often target single antigens (e.g., OspA), which may not capture the full antigenic complexity of natural infection or may fail to induce broad immunity against diverse strains. Furthermore, live-attenuated whole-cell vaccines must be safe (non-infectious) while retaining high immunogenicity.

2. Methodology

The study evaluated the potential of non-infectious B. burgdorferi mutant strains and their purified lipoproteins as "reservoir host-targeted biologics."

A. Strains Used:

• Parental Strain: B. burgdorferi B31-A3 (wild-type).
• Mutant Strains (Non-colonizing):
  • $\Delta$badR: Deletion of the badR regulator, leading to derepression of RpoS and hyper-expression of mammalian-phase lipoproteins.
  • 8S: Substitution of 8 conserved residues in Carbon Storage Regulator A (CsrA) with alanines, also causing RpoS upregulation and lipoprotein hyper-expression.
  • ML23: A strain lacking the lp25 plasmid (deficient in nicotinamidase), rendering it incapable of mammalian colonization.

B. Experimental Design:

1. Live Mutant Vaccination: C3H/HeN mice were immunized intradermally with live mutant strains.
   • Challenge: Mice were needle-challenged with wild-type B31-A3.
   • Transmission Block: Naïve I. scapularis larvae were allowed to feed on vaccinated mice to assess if they acquired the pathogen.
   • Long-term: A second experiment assessed protection over a longer duration (10 weeks post-challenge).
2. Lipoprotein Purification:
   • Lipoproteins were extracted from WT, 8S, and $\Delta$badR strains using Triton X-114 phase separation to enrich for membrane-associated lipoproteins (detergent phase) while removing soluble proteins like FlaB.
   • Proteomics: Mass spectrometry (LC-MS/MS) was used to characterize the protein composition and abundance of the purified lipoprotein fractions (PBLs).
3. Serological Analysis:
   • Reactivity of mouse infection-derived serum and blinded human Lyme disease patient serum against the mutants and PBLs was tested via ELISA and Western Blot.
   • Isotype profiling (IgM, IgG, IgG1, IgG2a, IgG2b) was conducted.
4. PBL Vaccination: Mice were immunized with purified lipoproteins (PBLs) from the mutants and challenged with Bb-infected nymphs.
5. Outcome Measures:
   • qPCR: Quantification of Bb burden in tick larvae and mouse tissues (skin, lymph nodes, joints, etc.).
   • Culture: Isolation of viable spirochetes from tissues in BSK-II medium.
   • Antibody Titers: ELISA measurements of specific IgG and isotypes.

3. Key Contributions

• Novel Biologic Strategy: Proposes the use of hyper-immunogenic, non-infectious mutant strains as live-attenuated vaccines for reservoir hosts, and their purified lipoproteins as subunit vaccines.
• Antigenic Complexity: Demonstrates that mutants with dysregulated RpoS expression present a broader array of surface-exposed lipoproteins (including OspA, OspB, OspC, DbpA/B, BBK32) compared to single-antigen recombinant vaccines.
• Transmission Blocking: Validates that inducing antibodies in reservoir hosts can prevent naïve larvae from acquiring the pathogen, effectively breaking the enzootic cycle.
• Human Relevance: Confirms that the lipoproteins expressed by these mutants are recognized by antibodies in human Lyme disease patients, suggesting their potential utility in diagnostics and vaccine design.

4. Key Results

A. Live Mutant Vaccination:

• Antibody Response: Vaccination with $\Delta$badR, 8S, or ML23 induced significant anti-Bb IgG titers.
• Transmission Blocking:
  • Mice vaccinated with ML23 completely prevented Bb acquisition by feeding larvae (0/3 mice positive).
  • Mice vaccinated with $\Delta$badR showed significant reduction in larval acquisition (only 1/3 positive).
  • 8S mutants showed variable protection (1/3 positive).
• Tissue Colonization:
  • $\Delta$badR provided the strongest protection against tissue colonization (14% infection rate vs. 100% in controls; $p=0.01$).
  • 8S and ML23 showed reduced but statistically non-significant infection rates in some tissue culture assays compared to controls, though they significantly reduced pathogen burden in ticks.
• Duration: Protection was observed at both 4 weeks and 10 weeks post-challenge, though efficacy varied by strain and time point.

B. Lipoprotein Characterization:

• Proteomics: The Triton X-114 detergent phase successfully enriched surface lipoproteins (OspA, OspB, OspC, OspD, LP6.6) and excluded the flagellin FlaB.
• Strain Differences: The 8S mutant exhibited significantly higher abundance of OspB compared to WT and $\Delta$badR. Mass spec confirmed OspB as a major immunogenic component in the 8S detergent fraction.
• Human Reactivity: Human sera from Lyme patients showed strong reactivity (IgM and IgG) to PBLs from all strains. Notably, reactivity to PBLs was often higher than to whole-cell lysates, suggesting PBLs contain highly immunodominant epitopes.

C. Purified Lipoprotein (PBL) Vaccination:

• Efficacy: Intradermal immunization with PBLs from WT (B31-A3) and 8S mutants conferred 100% protection against challenge with infected nymphs (0/6 mice infected; $p=0.01$).
• $\Delta$badR PBLs: Showed lower efficacy (33% infection rate), likely due to lower OspB abundance compared to the 8S strain.
• Immune Correlates: PBL vaccination induced strong IgG, IgG1, IgG2a, and IgG2b responses, indicating a mixed Th1/Th2 immune response essential for tissue clearance.

5. Significance and Conclusion

• Proof of Concept: The study successfully demonstrates that non-infectious B. burgdorferi mutants can serve as effective sources of immunogenic biologics.
• Reservoir-Targeted Control: By vaccinating reservoir hosts (e.g., via oral bait systems) with these mutants or their lipoproteins, it is possible to generate herd immunity that blocks transmission to ticks, thereby reducing human incidence.
• Superiority of Complex Antigens: The data suggests that lipoprotein complexes derived from mutants (mimicking the natural infection proteome) are more effective at inducing sterilizing immunity and blocking transmission than single recombinant antigens.
• Future Directions: The authors propose that PBLs from the 8S mutant are a prime candidate for a reservoir-targeted vaccine due to their high OspB content and superior protective efficacy in mouse models. Future work will focus on testing these formulations in natural reservoir hosts (Peromyscus leucopus) and developing oral delivery systems.

This research provides a robust framework for developing next-generation, transmission-blocking biologics to control Lyme disease at its ecological source.